|
Description |
Project Number |
Cost |
Project Title |
|
Cirrhosis Study |
5K24DK002727-09 |
$156,104 |
Cirrhosis and its complications |
|
Clinical Trial Chronic Liver Disease |
5U01AT003571-03 |
$82,500 |
Clinical Center for Phase I/II trials of Silymarin
in Chronic Liver Disease |
|
$399,856
|
5U01AT003560-03 |
$71,088 |
A phase I/II randomized, placebo controlled trial of
silymarin for hepatitis C |
| |
5U01AT003566-03 |
$169,852 |
Phase I/II Trials of Silymarin for Chronic Liver
Diseases Data Coordinating Cente |
| |
5U01AT003573-03 |
$76,416 |
A phase I/II trial of silymarin for chronic liver
diseases |
|
HBV/Viral Hep Study |
1Z01DK054514-02 |
$448,652 |
Investigation of management and disease
manifestations of viral hepatitis |
|
$1,084,510
|
1Z01DK054509-11 |
$473,033 |
Immunology of Acute and Chronic Viral Hepatitis in
Humans |
| |
5K24DK078772-02 |
$162,825 |
Patient-Oriented Research on Hepatitis in Special
Populations |
|
HCC Study |
5R01DK066840-05 |
$345,537 |
Novel markers for HCV-related HCC |
|
$1,331,388
|
5R01DK069859-03 |
$482,550 |
Genes Related to HCC Progression in LD and DD
Transplant |
| |
1Z01DK054504-12 |
$503,301 |
Animal And Culture Models of Viral Hepatitis And
Hepatocellular Carcinoma |
|
HCV Based Study |
1R01DK080711-01 |
$294,000 |
Hepatitis C Virus Quasispecies in the Resistance to
Antiviral Therapy |
|
$6,435,330
|
3R01DK074515-02S1 |
$13,452 |
Role of HCV Sequence Variation in Pathology |
| |
5R21DK074891-02 |
$145,040 |
Novel model of HCV infection of humanized liver in
immunocompetent rats |
| |
1R01DK077704-01A2 |
$328,313 |
Viral Hepatitis C and Lipid Homeostasis |
| |
5K08DK070022-05 |
$128,946 |
Insulin Resistance in Hepatitis C Virus Infection |
| |
5R01DK062847-06 |
$87,788 |
Molecular Determinants of HCV Replication |
| |
5K08DK076598-02 |
$124,308 |
The Pathogenesis of Steatosis in Hepatitis C
Genotype 3 Infection |
| |
5F32DK067781-03 |
$52,048 |
Cis- and Trans-acting Factors in HCV Gene Expression |
| |
5R01DK066754-05 |
$282,304 |
Impaired T cell function by HCV core |
| |
1Z01DK054511-02 |
$466,145 |
The Genetics of Disease Progression and Treatment
Response in Hepatitis C |
| |
5R01DK064223-05 |
$261,667 |
HCV NS5A: Molecular Virology and Antiviral Target |
| |
5R01DK078857-02 |
$279,351 |
Interferon modulation of cellular microRNAs in the
Hepatitis C antiviral defense |
| |
5K08DK076565-02 |
$121,770 |
Bias in Retransplantation Survival Models: Selection
Criteria and Hepatitis C |
| |
5R01DK074515-02 |
$318,528 |
Role of HCV Sequence Variation in Pathology |
| |
1R01DK074673-01A2 |
$457,981 |
Impact of Hepatitis C on Insulin Sensitivity and
Insulin Secretion in Latinos |
| |
5K24DK066144-05 |
$139,317 |
Mentoring Junior Faculty: Hepatitis C Clinical
Research |
| |
1Z01DK075009-03 |
$378,094 |
Natural History, Therapy and Pathogenesis of Chronic
Viral Hepatitis C |
| |
5F32DK081193-02 |
$52,898 |
Characterization of the HCV p7 Protein |
| |
1F32DK083237-01A2 |
$49,646 |
Molecular mechanism of cellular activation of the
hepatitis C virus polymerase |
| |
5R01DK066802-05 |
$352,173 |
PATHOPHYSIOLOGY OF CRYOGLOBULINEMIC
GLOMERULONEPHRITIS |
| |
1R43DK083104-01 |
$305,200 |
Towards the creation of HCV-resistant liver cells
for transplantation |
| |
1Z01DK054503-12 |
$506,679 |
Molecular Approaches To Vaccine Development For
Hepatitis C |
| |
1K01DK081736-01 |
$157,946 |
Genetic Epidemiology of HCV-related Liver Disease |
| |
5R01DK068361-03 |
$241,111 |
Role of immature DC in host defense against HCV |
| |
5F32DK081259-02 |
$49,646 |
Structural and Functional Studies of Hepatitic C
Core and NS4B Proteins |
| |
5R21DK079293-02 |
$179,463 |
Transgenic mouse models of hepatitis C virus
replication |
| |
5F32DK079860-02 |
$49,646 |
Characterization of the Assembly and Egress Pathway
of Hepatitis C Virus |
| |
5R01DK066939-05 |
$370,132 |
Modulation of HCV Gene Expression |
| |
5R01DK070877-03 |
$186,896 |
Immunoglobulin Allotypes in Hepatitis C Virus
Infection |
| |
1F32DK083252-01 |
$54,842 |
Interactions Between Hepatitis C and Serum Lipid
Homeostasis |
|
HIV/HCV Kidney Disease |
5K23DK077568-02 |
$129,225 |
Kidney Disease in HIV-Hepatitis C Virus Co-Infection |
|
$355,371
|
1F32DK082155-01 |
$44,846 |
The role of interferon-stimulated genes in antiviral
immunity |
| |
5R21DK077575-02 |
$181,300 |
Liver Disease Associated with HCV/HIV Coinfection
Due to TRAIL |
|
Interferon/Antivial Treatment HCV Study |
3U01DK067767-05S1 |
$500,000 |
Pegylated Interferon +/- Ribavirin for Children with
HCV |
|
$1,506,950
|
5R01DK071560-04 |
$270,459 |
Innate Immune Responses During Therapy for Chronic
HCV |
| |
5R21DK078100-02 |
$181,912 |
Ribavirin Pharmacokinetics, Race and HCV Treatment |
| |
1Z01DK054505-12 |
$503,301 |
Mechanisms of Interferon Action and Resistance in
Hepatitis C Virus Infection |
| |
5F32DK080650-02 |
$51,278 |
Viral Dynamics of HCV Serine Protease Inhibitor
Resistance |
|
Interferon/Antivial Treatment HIV/HCV Study |
2R01DK063222-05A2 |
$257,550 |
Role of NK in Regulation of anti-viral T cell
immunity |
|
Liver Disease Study |
5K24DK078154-02 |
$149,057 |
Epidemiology and Outcomes of Digestive and Liver
Diseases: A Mentoring Program |
|
$6,035,969
|
5R01DK070844-03 |
$256,328 |
Transplantation of Reduced-Size Fatty Livers |
| |
1R43DK080549-01 |
$255,501 |
TGFb1 Receptor Inhibitors for Liver Fibrosis |
| |
5K24DK070528-04 |
$117,084 |
Mentorship in Liver Disease |
| |
5U01DK062536-07 |
$380,389 |
Adult to adult living donor liver transplantation
cohor* |
| |
1Z01DK054515-02 |
$305,182 |
Immune responses in autoimmune liver diseases |
| |
5P01DK058327-09 |
$253,222 |
Liver-directed Gene Therapy for Alpha 1 Antitrypsin
(AAT) Deficiency |
| |
1F30DK082151-01 |
$30,622 |
Regulation of hepcidin and iron metabolism in liver
disease |
| |
1R41DK082087-01 |
$151,754 |
Automated quantification of lipid droplets in fatty
liver tissue sections |
| |
5U01DK062498-07 |
$756,259 |
Living donor liver transplant data coordinating
center |
| |
5U01DK062531-07 |
$208,685 |
Adult to Adult Living Donor Liver Transplantation |
| |
5U01DK062505-07 |
$1 |
Right Lobe Living Donor Liver Transplantation in
Adults |
| |
5U01DK062444-07 |
$252,773 |
Adult to Adult Living Donor Liver Transplantation
Cohort |
| |
5R21DK073649-02 |
$186,200 |
MRI Quantification & Display of Hepatic Fat in
Hepatitis C & NAFLD Patients |
| |
5U01DK062494-07 |
$119,233 |
Adult to Adult Living Donor Liver Transplantation
Cohort Study |
| |
5U01DK062467-07 |
$465,991 |
Adult Live Donor Liver Transplant-A Comparative
Analysis |
| |
5U01DK062483-07 |
$244,267 |
Adult to Adult Living Donor Liver Transplantation
Cohort Study |
| |
5U01DK062484-07 |
$170,038 |
Living Donor Liver Transplantation Cohort Study |
| |
5U01DK061693-05 |
$1,065,842 |
Studies of Pediatric Liver Transplantation |
| |
5K24DK072036-04 |
$194,250 |
Racial Disparities in Liver Diseases |
| |
5R01DK066917-05 |
$197,460 |
Innate-like hepatic CD1d-reative NKT cells:Liver
Disease |
| |
5R01DK073192-03 |
$154,566 |
Liver Regeneration in the Transplant Setting |
| |
5U01DK062496-07 |
$121,265 |
ADLDT: An Opportunity to Expand the National Donor
Pool |
|
Liver Transplant HCV |
5R01DK065982-05 |
$334,102 |
Immune Response to Hepatitis C in Liver
Transplantation |
|
Other Treatment Study |
5R01DK068598-04 |
$373,299 |
Racial Differences in IFN Transcriptional Response |
|
$863,472 |
1Z01DK031128-02 |
$200,250 |
Development of Nucleoside Derivatives for
Nonreceptor Targets |
| |
1Z01DK054508-11 |
$289,923 |
Analysis and Modulation of Virus-Host Interaction in
Animal Models |
| |
|
|
|
| |
|
$18,760,602 |
|
